MedPath

Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy

Not Applicable
Terminated
Conditions
Breast Neoplasms
Interventions
Procedure: Completion axillary treatment
Registration Number
NCT02112682
Lead Sponsor
Maastricht University Medical Center
Brief Summary

STUDY AIM To decrease the number of breast cancer patients receiving overtreatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life.

PRIMARY OBJECTIVE To determine whether omitting completion axillary treatment is not inferior to the current axillary treatment regimen in sentinel node positive breast cancer patients undergoing a mastectomy, in terms of regional recurrence rate.

HYPOTHESIS Completion axillary treatment can be safely omitted in sentinel node positive breast cancer patients undergoing a mastectomy. This will lead to a decreased axillary morbidity rate and to an increased quality of life, with non-inferior regional control, distant-disease free- and overall survival rates.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
52
Inclusion Criteria
  • Female
  • Aged 18 years or older
  • Pathologically confirmed invasive unilateral breast carcinoma
  • A clinical T1-2 tumour (including multifocal or multicentric breast cancer)
  • Will be or is treated with mastectomy
  • Clinically node negative: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology)
  • Sentinel lymph node procedure and its pathologic evaluation should be performed according to the Dutch breast cancer guideline
  • pN1mi(sn) or pN1(sn): at least one and a maximum of three axillary sentinel lymph nodes containing micro- and/or macrometastases
  • Written informed consent
Exclusion Criteria
  • Clinically node positive pre-operative
  • Sentinel lymph nodes only containing isolated tumour cells (<0.2 mm)
  • Solitary parasternal sentinel lymph node metastasis (pN1b)
  • Bilateral breast cancer
  • Irradical resection of primary tumour at time of randomization (applicable in case the mastectomy is performed before randomization)
  • Evidence of metastatic disease
  • History of invasive breast cancer
  • Previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi)
  • Pregnant or nursing
  • Other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies > 5 years before randomization
  • Unable or unwilling to give informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Completion axillary treatmentCompletion axillary treatmentCompletion axillary treatment according to the Dutch breast cancer guideline
Primary Outcome Measures
NameTimeMethod
Regional recurrence rateup to ten years

Regional recurrence is defined as tumour recurrence and as residual tumour that became clinically apparent in ipsilateral axillary, infraclavicular and supraclavicular lymph nodes (pathologically proven).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Martini Ziekenhuis

🇳🇱

Groningen, Netherlands

Alrijne ziekenhuis

🇳🇱

Leiden, Netherlands

Rijnstate

🇳🇱

Arnhem, Netherlands

Tergooi

🇳🇱

Hilversum, Netherlands

Amphia ziekenhuis

🇳🇱

Breda, Netherlands

Meander Medisch Centrum

🇳🇱

Amersfoort, Netherlands

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

🇳🇱

Amsterdam, Netherlands

Flevoziekenhuis

🇳🇱

Almere, Netherlands

Maastricht University Medical Centre+

🇳🇱

Maastricht, Limburg, Netherlands

Gelre Ziekenhuizen

🇳🇱

Apeldoorn, Netherlands

St. Elisabeth Ziekenhuis

🇳🇱

Tilburg, Netherlands

Reinier de Graaf

🇳🇱

Delft, Netherlands

Haga Ziekenhuis

🇳🇱

Den Haag, Netherlands

Deventer Ziekenhuis

🇳🇱

Deventer, Netherlands

Jeroen Bosch ziekenhuis

🇳🇱

Den Bosch, Netherlands

Bronovo / Medisch Centrum Haaglanden

🇳🇱

Den Haag, Netherlands

Catharina Ziekenhuis Eindhoven

🇳🇱

Eindhoven, Netherlands

Groene Hart Ziekenhuis

🇳🇱

Gouda, Netherlands

Medisch Spectrum Twente

🇳🇱

Enschede, Netherlands

Zuyderland Medisch Centrum

🇳🇱

Sittard, Netherlands

UMC Groningen

🇳🇱

Groningen, Netherlands

St. Antonius Ziekenhuis

🇳🇱

Nieuwegein, Netherlands

Canisius-Wilhelmina Ziekenhuis

🇳🇱

Nijmegen, Netherlands

Radboud university medical center

🇳🇱

Nijmegen, Netherlands

Laurentius Ziekenhuis

🇳🇱

Roermond, Netherlands

Antonius Ziekenhuis

🇳🇱

Sneek, Netherlands

Rivierenland

🇳🇱

Tiel, Netherlands

Diakonessenhuis Utrecht

🇳🇱

Utrecht, Netherlands

Isala Klinieken

🇳🇱

Zwolle, Netherlands

Maxima Medisch Centrum

🇳🇱

Veldhoven, Netherlands

© Copyright 2025. All Rights Reserved by MedPath